Having trouble accessing articles? Reset your cache.

Retaspimycin: Development discontinued

Infinity discontinued development of IPI-504 to treat breast cancer after an interim review of data from 26 HER2-positive metastatic breast cancer patients enrolled in the first cohort of an open-label Phase II trial showed that once-weekly 300 mg/m 2 IV

Read the full 407 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers